Christophe Bonaldi

Christophe Bonaldi

Auto-generated profile, based on publicly available information

Christophe Bonaldi

Direction Appui, Traitements et Analyses de données (C.B.), Santé publique, Saint-Maurice, France

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2016 in Annals of Epidemiology
Verified
Journal Article
Closed access
YBYaya Barry
Yaya Barry
CBChristophe Bonaldi
Christophe Bonaldi
VGVéronique Goulet
Véronique Goulet
RCRégis Coutant
Régis Coutant
JLJuliane Léger
Juliane Léger
MRMichel Roussey
Michel Roussey

12 April 2011 in Diabetic Medicine
Verified
Journal Article
Closed access
PDF file
CBC. Bonaldi
C. Bonaldi
MVM. Vernay
M. Vernay
CRC. Roudier
C. Roudier
BSB. Salanave
B. Salanave
AOA. Oleko
A. Oleko
AFA. Fagot‐Campagna
A. Fagot‐Campagna

1 November 2020 in Diabetes & Metabolism
Verified
Journal Article
Closed access
SFS. Fuentes
S. Fuentes
LML. Mandereau-Bruno
L. Mandereau-Bruno
NRN. Regnault
N. Regnault
PBP. Bernillon
P. Bernillon
CBC. Bonaldi
C. Bonaldi
SFS. Fosse-Edorh
S. Fosse-Edorh

7 May 2018 in European Journal of Public Health
Verified
Journal Article
Closed access
PDF file
BCBochen Cao
Bochen Cao
CHCatherine Hill
Catherine Hill
CBChristophe Bonaldi
Christophe Bonaldi
MLMaria E León
Maria E León
GMGwenn Menvielle
Gwenn Menvielle
ISIsabelle Soerjomataram
Isabelle Soerjomataram
The evidence on the carcinogenicity of tobacco smoking has been well established. An assessment of the population-attributable fraction (PAF) of cancer due to smoking is needed for France, given its high smoking prevalence. We extracted age- and sex-specific national estimates of population and cancer incidence for France, and incidence rates of lung cancer among never smokers and relative risk (RR) estimates of smoking for various cancers from the American Cancer Prevention Study (CPS II). For active smoking, we applied a modified indirect method to estimate the PAF for lung and other tobacco smoking-related cancer sites. Using the RR estimates for second-hand smoking, the proportion of never smokers living with an ever-smoking partner derived from survey, and marital status data, we then estimated the PAF for lung cancer attributable to domestic passive smoking. Overall in France in 2015, 54 142 and 12 008 cancer cases in males and females, respectively, were attributable to active smoking, accounting for 28 and 8% of all cancer cases observed among adult (30+ years) males and females. Additionally, 36 and 142 lung cancer cases, respectively among male and female never smokers, were attributable to second-hand smoke resulting from their partner’s active smoking, corresponding to 4.2 and 6.7% of lung cancer cases which occurred in never smoker males and females, respectively. Tobacco smoking is responsible for a significant number of potentially avoidable cancer cases in France in 2015. More effective tobacco control programmes are critical to reduce this cancer burden.

22 August 2017 in Addiction
Verified
Journal Article
Closed access
PDF file
KSKevin David Shield
Kevin David Shield
CMClaire Marant Micallef
Claire Marant Micallef
CHCatherine Hill
Catherine Hill
MTMathilde Touvier
Mathilde Touvier
PAPierre Arwidson
Pierre Arwidson
ISIsabelle Soerjomataram
Isabelle Soerjomataram

11 November 2019 in European Journal of Public Health
Verified
Journal Article
Closed access
VOValérie Olié
Valérie Olié
APAnne Pasquereau
Anne Pasquereau
FAFrank A G Assogba
Frank A G Assogba
PAPierre Arwidson
Pierre Arwidson
VNViet Nguyen-Thanh
Viet Nguyen-Thanh
CBChristophe Bonaldi
Christophe Bonaldi
Background: The high prevalence of smoking among French women since the 1970s has been reflected over the past decade by a strong impact on the health of women. This paper describes age and gender differences in France of the impact of smoking on morbidity and mortality trends since the 2000s. Methods: Smoking prevalence trends were based on estimates from national surveys from 1974 to 2017. Lung cancer incidence were estimated from 2002–12 cancer registry data. Morbidity data for chronic obstructive pulmonary disease (COPD) exacerbation and myocardial infarction were assessed through hospital admissions data, 2002–15. For each disease, number of deaths between 2000 and 2014 came from the national database on medical causes of death. The tobacco-attributable mortality (all causes) was obtained using a population-attributable fraction methodology. Results: The incidence of lung cancer and COPD increased by 72% and 100%, respectively, among women between 2002 and 2015. For myocardial infarction before the age of 65, the incidence increased by 50% between 2002 and 2015 in women vs. 16% in men and the highest increase was observed in women of 45–64-year-olds. Mortality from lung cancer and COPD increased by 71% and 3%, respectively, among women. The estimated number of women who died as a result of smoking has more than doubled between 2000 and 2014 (7% vs. 3% of all deaths). Conclusions: The increase in the prevalence of smoking among women has a major impact on the morbidity and mortality of tobacco-related diseases in women and will continue to increase for a number of years.